DABIGATRAN TEVA 110 MG

Država: Izrael

Jezik: angleščina

Source: Ministry of Health

Aktivna sestavina:

DABIGATRAN ETEXILATE AS MESYLATE

Dostopno od:

TEVA ISRAEL LTD

Koda artikla:

B01AE07

Farmacevtska oblika:

CAPSULES

Sestava:

DABIGATRAN ETEXILATE AS MESYLATE 110 MG

Pot uporabe:

PER OS

Tip zastaranja:

Required

Izdeluje:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Terapevtsko območje:

DABIGATRAN ETEXILATE

Terapevtske indikacije:

Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults

Datum dovoljenje:

2020-11-01

Navodilo za uporabo

PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS
(PREPARATIONS) – 1986
The medicine is dispensed with a doctor’s
prescription only
DABIGATRAN TEVA 110 MG
CAPSULES
THE ACTIVE INGREDIENT:
Each capsule of DABIGATRAN TEVA 110 MG contains:
110 mg dabigatran etexilate (as mesylate)
For information about inactive ingredients see section
6 – “Additional information”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE
MEDICINE.
This leaflet contains concise information about the
medicine. If you have additional questions, refer to the
doctor or the pharmacist.
This medicine has been prescribed for treatment of your
illness. Do not pass it on to others. It may harm them even
if it seems to you that their illness is similar.
Patient information card:
This card contains important safety information,
which you need to know before starting treatment
with Dabigatran Teva and during the treatment with
Dabigatran Teva. The card contains information intended
for both the patient and the healthcare staff. It provides
guidance for patients on how to minimize the risk of
bleeding, which results from treatment with any of the
anticoagulant preparations.
In addition, the card contains personal details of
the patient and information regarding the medicine
Dabigatran Teva for the healthcare staff. Present this card
to any healthcare professional involved in your treatment.
1. WHAT IS THE MEDICINE INTENDED FOR?
Dabigatran Teva contains the active ingredient dabigatran
etexilate, which belongs to a group of medicines called
“anticoagulants”. Dabigatran Teva is intended for adults:
1. For primary prevention of thrombosis of the veins
following elective orthopedic surgeries of total knee
replacement or total hip replacement.
2. For the prevention of stroke and systemic embolism in
adult patients suffering from irregular heartbeat (atrial
fibrillation) that is unrelated to valve disease.
3. For the treatment of blood clots in the leg veins (deep
vein thrombosis (DVT)) and in the pulmonary blood
vessels (pulmonar